SPDR S&P Biotech ETF

Fund Name:
SPDR S&P Biotech ETF
State Street
Total Net Assets:
Related Index:
s&p biotechnology select industry index
ETF Category: 
Expense Ratio: 
Net Asset Value: 
Recent NAV Premium: 
NAV Symbol: 
Number of Holdings: 
Annualized Yield: 
Annualized Distribution: 
Stock Weight Amount
Mirati Therapeutics 1.61% $87,697,809
Immunovant 1.58% $85,797,168
Ionis Pharmaceuticals 1.41% $76,519,623
Seagen 1.39% $75,738,323
Neurocrine Biosciences 1.37% $74,547,640
List of all 135 stocks held by XBI »
Quotes delayed 20 minutes

Email EnvelopeFree XBI Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Buy (3.43 out of 4)
93rd percentile
(ranked higher than approx. 93% of all etfs covered)
Based on data provided by Zacks Investment Research via
ETF Assets
SPY   $405,020,103,761
GLD   $51,301,724,631
XLK   $48,242,712,835
XLV   $38,052,508,002
XLE   $38,000,001,601
List of all 142 others »
Shares Short 42,130,000
Chg. from Last Month +1,420,000
Shares Outstanding 75,220,000
% of Shares Short 56.01%
Days to Cover 5.4
Based on third party short interest data.

XBI | SPDR S&P Biotech ETF | ETF Channel |

Copyright © 2010 - 2023, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.